iRay Group (688301) Fair Value & Analysis
Healthcare · CN · Market cap 33.1B CNY
Analysis
iRay Group (688301) currently trades at ¥110.76, while our model-based Fair Value estimate is ¥37.19 — implying the stock looks roughly 66.4% overvalued today. We read business quality at 80/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
iRay Group, together with its subsidiaries, researches, develops, produces, sells, and services x-ray system components and micro-display backplanes for use in medical, dental, oncology, veterinary, security, and nondestructive testing applications in China and internationally. The company offers wireless and tethered radiography, mammography, and dynamic/real-time detectors; linear detector arrays; X-ray and micro focus X-ray sources; high voltage generators; radiation detecting materials; software; and other products. It is also involved in the technology and product development; customer service; and investment and management activities. The company exports its products to approximately 80 countries. The company was formerly known as iRay Technology Company Limited and changed its name to iRay Group in February 2025. iRay Group was incorporated in 2011 and is headquartered in Shanghai, China.
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.